ITEOS THERAPEUTICS IN

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

08 4 2022 13:00:00 提供 Nasdaq GlobeNewswire

iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

23 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

iTeos to Present at the Cowen 42nd Annual Health Care Conference

01 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

iTeos to Participate in Upcoming Investor Conferences in February

10 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

10 1 2022 07:00:02 提供 Nasdaq GlobeNewswire

iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 1 2022 16:01:00 提供 Nasdaq GlobeNewswire

iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021

09 12 2021 16:01:00 提供 Nasdaq GlobeNewswire

iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

10 11 2021 16:01:00 提供 Nasdaq GlobeNewswire

iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

03 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

iTeos Therapeutics to Participate in Upcoming September Investor Conferences

01 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update

12 8 2021 07:00:01 提供 Nasdaq GlobeNewswire

iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021

03 8 2021 07:00:01 提供 Nasdaq GlobeNewswire

iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021

08 7 2021 10:03:50 提供 Nasdaq GlobeNewswire

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

14 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021

04 6 2021 09:00:00 提供 Nasdaq GlobeNewswire

iTeos Reports First Quarter 2021 Financial Results and Provides Business Update

13 5 2021 16:01:00 提供 Nasdaq GlobeNewswire

iTeos to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 13, 2021

06 5 2021 16:01:01 提供 Nasdaq GlobeNewswire

iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors

03 5 2021 16:01:00 提供 Nasdaq GlobeNewswire

iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021

10 4 2021 08:30:00 提供 Nasdaq GlobeNewswire

iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

24 3 2021 16:45:00 提供 Nasdaq GlobeNewswire